Q3 2025 AtriCure Inc Earnings Call Transcript
Key Points
- AtriCure Inc (ATRC) reported a strong third quarter with total revenue of $134 million, reflecting a 16% increase year over year.
- The company achieved nearly $18 million in adjusted EBITDA and generated over $30 million in cash during the third quarter.
- Product innovation and clinical science initiatives are driving growth, with successful launches of the AtriClip, FLEX Mini, and cryoSPHERE MAX devices.
- The EnCompass clamp is contributing to accelerated growth in Europe and steady growth in the United States.
- The company raised its full-year revenue guidance to approximately $532 million to $534 million, reflecting 14% to 15% growth compared to 2024.
- The minimally invasive ablation sales declined to $7.4 million for the quarter.
- The hybrid therapy market dynamics remain challenging in the US due to increased adoption of PFA catheter technology.
- There is a sequential step down in adjusted EBITDA expected for the fourth quarter, indicating potential conservatism or increased R&D spending.
- The company anticipates no immediate revenue from the recent approvals in Japan, with market preparation expected over the next six months.
- The hybrid business has been experiencing softness, with pressure from PFA technologies affecting growth.
Good afternoon and welcome to AtriCure's third quarter 2025 earnings conference call. This call is being recorded for replay purposes, and at this time all participants are in listen-only mode. We will be facilitating a question-and-answer session following prepared remarks from AtriCure's management.
I would now like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.
Thank you. By now you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one emailed to you. Before we begin today, let me remind you that the company's remarks include forward-looking statements.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to financial expectations and guidance, expectations regarding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
